RESUMO
Progressive multifocal leukoencephalopathy is a rare demyelinating disorder of the CNS, caused by John Cunningham virus, that occurs in those with impaired immune systems. Existing treatment options are ineffective or unproven. This article reviews research into novel therapies: immune checkpoint-blocking antibodies (nivolumab and pembrolizumab), allogenic BK virus-specific T cell treatment and filgrastim. Results for these therapies in small clinical trials are promising, but further research is required to assess efficacy fully.
Assuntos
Hospedeiro Imunocomprometido , Leucoencefalopatia Multifocal Progressiva/tratamento farmacológico , Idoso , Anticorpos Monoclonais Humanizados/uso terapêutico , Antineoplásicos Imunológicos/uso terapêutico , Filgrastim/uso terapêutico , Humanos , Vírus JC , Leucoencefalopatia Multifocal Progressiva/virologia , Masculino , Nivolumabe/uso terapêutico , Receptor de Morte Celular Programada 1/antagonistas & inibidoresRESUMO
PML should be considered in patients with neurological symptoms following MM and in those who are immunosuppressed. Symptoms are diverse and often rapidly progressing. Prompt referral and early involvement of the multidisciplinary team are crucial.
